Sharma M.
200
Coauthors
5
Documentos
Volumen de publicaciones por año
Cargando gráfico
Año de publicación | Num. Publicaciones |
---|---|
2017 | 1 |
2019 | 1 |
2020 | 1 |
2021 | 1 |
2022 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
Área de conocimiento | Num. Publicaciones |
---|---|
Enfermedad cardiovascular | 4 |
Medicina interna | 3 |
Neurología | 1 |
Medicamento | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
Área temática | Num. Publicaciones |
---|---|
Enfermedades | 5 |
Medicina y salud | 3 |
Farmacología y terapéutica | 2 |
Cirugía y especialidades médicas afines | 2 |
Principales fuentes de datos
Origen | Num. Publicaciones |
---|---|
Scopus | 5 |
Google Scholar | 4 |
RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
Coautor | Num. Publicaciones |
---|---|
Dagenais G.R. | 5 |
Branch K.R.H. | 5 |
Yusuf S. | 5 |
Bhatt D.L. | 5 |
Avezum A.J. | 5 |
Eikelboom J.W. | 5 |
Connolly S.J. | 5 |
Fox K.A.A. | 5 |
Maggioni A.P. | 5 |
Bosch J.J. | 5 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
ArticleAbstract: Background: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily comparedPalabras claves:aspirin, Coronary artery disease, Mortality , Peripheral artery disease, rivaroxabanAutores:Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Connolly S.J., Dagenais G.R., Eikelboom J.W., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Maggioni A.P., Muehlhofer E., Sharma M., Shestakovska O., Yusuf S.Fuentes:googlescopusRivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy
ArticleAbstract: Background and Purpose: Covert brain infarcts are associated with cognitive decline. It is not knownPalabras claves:aspirin, COGNITION, infarction, rivaroxaban, white matterAutores:Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Casanova A., Connolly S.J., Dagenais G.R., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Fox K.A.A., Hart R.G., Keltai K., Keltai M., Kim J.H., Liang Y., Liu L., Lonn E.M., Maggioni A.P., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Reeh K.W., Rydén L.E., Sharma M., Smith E.E., Störk S., Tonkin A.M., Varigos J.D., Vinereanu D., Yusuf S., Zhu J.Fuentes:googlescopusRationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial
ArticleAbstract: Background: Covert vascular disease of the brain manifests as infarcts, white matter hyperintensitiePalabras claves:Anticoagulant, Clinical trial, COGNITION, magnetic resonance imaging, prevention, silent infarctAutores:Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Casanova A., Connolly S.J., Cook-Bruns N., Dagenais G.R., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Ha J.W., Hart R.G., Keltai K., Keltai M., Kim J.H., Liang Y., Liu L., Lonn E.M., Maggioni A.P., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Smith E.E., Störk S., Tonkin A.M., Varigos J.D., Vinereanu D., Wong G., Yuan F., Yusuf S., Zhu J.Fuentes:googlescopusLong-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
ArticleAbstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheralPalabras claves:aspirin, Coronary artery disease, Peripheral artery disease, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.Fuentes:scopusRationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
ArticleAbstract: Background Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alPalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Ha J.W., Hart R.G., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Lanius V., Leong D.P., Lewis B.S., Liang Y., Liu L., Lonn E.M., Maggioni A.P., Metsarinne K.P., Misselwitz F., Moayyedi P., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yuan F., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopus